Neurocrine Biosciences, Inc. (LON:0K6R)

Market Cap	9.52B
Revenue (ttm)	1.88B
Net Income (ttm)	272.62M
Shares Out	n/a
EPS (ttm)	2.63
PE Ratio	34.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196
Average Volume	919
Open	120.74
Previous Close	116.96
Day's Range	118.50 - 122.33
52-Week Range	89.66 - 143.27
Beta	n/a
RSI	35.34
Earnings Date	Feb 7, 2025

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD